Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL665968 | 0.92 | PARP1 (0.59) | PARP1POLBHRH3BCHEACHE | |
| SCHEMBL663661 | 0.81 | PARP1 (0.45) | PARP1POLBCYP2D6RAB9ASMN1; SMN2 | |
| SCHEMBL6755331 | 0.78 | ALDH1A1 (0.48) | PARP1POLBBCHEACHEEPHX2 | |
| SCHEMBL665148 | 0.77 | PARP1 (0.50) | PARP1ACHEEPHX2HTR3A | |
| SCHEMBL630603 | 0.76 | PARP1 (1.00) | PARP1 | |
| SCHEMBL666514 | 0.76 | PARP1 (0.59) | PARP1POLBBCHEACHEEPHX2 | |
| SCHEMBL6753927 | 0.75 | BCHE (0.46) | PARP1POLBBCHEACHEEPHX2 | |
| SCHEMBL662573 | 0.75 | RAB9A (0.43) | PARP1POLBEPHX2CYP2D6TP53 | |
| SCHEMBL664160 | 0.74 | CHRNA7 (0.43) | PARP1ACHEEPHX2RAB9A | |
| SCHEMBL665626 | 0.74 | PARP1 (0.60) | PARP1POLBBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324829-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-20150005354-A1 | Combination Therapy With Parp Inhibitors | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20150005355-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. | 2015-01-01 | — | — | US | disclosed |
| US-20130225647-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120264795-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBVIE INC. | 2012-10-18 | — | — | US | disclosed |
| US-20120190720-A1 | Combination Therapy With Parp Inhibitors | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20090029966-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080293795-A1 | temozolomide and veliparib for breast cancer | ABBOTT LABORATORIES | 2008-11-27 | — | — | US | disclosed |
| US-20080280867-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080146638-A1 | primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP) | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | US | disclosed |
| US-20070265324-A1 | Combination Therapy with Parp Inhibitors | ABBOTT LABORATORIES | 2007-11-15 | — | — | US | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151023-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
| US-20160324829-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 109/4885HRH3 2988/4885 |
| US-20090029966-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 109/4885HRH3 2988/4885 |
| US-20150005354-A1 | Combination Therapy With Parp Inhibitors | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
| US-20070265324-A1 | Combination Therapy with Parp Inhibitors | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
| US-20130225647-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
| US-20080146638-A1 | primary small cell lung cancer with veliparib and temozolomide; poly/adp-ribose/polymerase (PARP) | PARP1, PARP2, PARP3 | PARP1 1/4885POLB 54/4885HRH3 2447/4885 |
| US-20110152336-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
| US-20120045524-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | PARP1 1/4885POLB 60/4885HRH3 2062/4885 |
| US-20080293795-A1 | temozolomide and veliparib for breast cancer | PARP1, PARP2, BRCA1 | PARP1 1/4885POLB 139/4885HRH3 3475/4885 |
| US-20080280867-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 109/4885HRH3 2988/4885 |
| US-20150005355-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 109/4885HRH3 2988/4885 |
| US-20120264795-A1 | COMBINATION THERAPY WITH PARP INHIBITORS | PARP1, PARP2, PARP12 | PARP1 1/4885POLB 185/4885HRH3 1975/4885 |
| US-20120190720-A1 | Combination Therapy With Parp Inhibitors | PARP2, PARP1, PARP3 | PARP1 2/4885POLB 59/4885HRH3 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.